Table 1.
Patient Data
| Patient ID | Vh:Cd (time, 0 days) | Vh:Cd (time, 42 days) | ΔVh:Cd (time 0 - time 42) | Gluten challenge, g/day | Age range, y | Sex | Anti–TG2-IgA (time, 0 days) | Anti–TG2-IgA (time, 42 days) | Anti–TG2-IgA fold change | Anti–TG2-IgA positivity |
|---|---|---|---|---|---|---|---|---|---|---|
| Z | 3.1 | 0.2 | 2.9 | 6 | 41–50 | F | 7 | 216 | 31 | Pos |
| X | 3.1 | 0.2 | 2.9 | 6 | 51–60 | F | 6 | 8 | - | Neg |
| AV | 3.1 | 0.2 | 2.9 | 3 | 61–70 | F | 17 | 183 | 11 | Pos |
| O | 3.5 | 0.7 | 2.8 | 6 | 51–60 | F | 8 | 146 | 18 | Pos |
| P | 2.7 | 0.2 | 2.5 | 6 | 41–50 | F | 11 | 227 | 21 | Pos |
| AS | 3.2 | 0.7 | 2.5 | 3 | 51–60 | M | 11 | 8 | - | Neg |
| M | 2.9 | 0.5 | 2.4 | 6 | 61–70 | M | 12 | 19 | - | Neg |
| Y | 2.8 | 0.4 | 2.4 | 6 | 51–60 | F | 10 | 10 | - | Neg |
| G | 2.6 | 0.3 | 2.3 | 6 | 31–40 | M | 6 | 240 | 40 | Pos |
| W | 2.6 | 0.3 | 2.3 | 6 | 41–50 | F | 6 | 53 | 9 | Pos |
| AF | 2.7 | 0.4 | 2.3 | 3 | 41–50 | M | 23 | 40 | - | Baseline pos |
| R | 3 | 0.8 | 2.2 | 6 | 61–70 | F | 7 | 10 | - | Neg |
| AW | 2.8 | 0.6 | 2.2 | 3 | 41–50 | F | 15 | 85 | 6 | Pos |
| K | 2.4 | 0.3 | 2.1 | 6 | 41–50 | F | 15 | 282 | 19 | Pos |
| CM | 2.8 | 0.7 | 2.1 | 1.5 | 41–50 | F | 10 | 72 | 7 | Pos |
| AQ | 2.4 | 0.4 | 2 | 3 | 61–70 | F | 10 | 22 | 2 | Pos |
| AY | 2.6 | 0.6 | 2 | 3 | 61–70 | M | 12 | 36 | 3 | Pos |
| AC | 2.3 | 0.3 | 2 | 3 | 61–70 | M | 7 | 11 | - | Neg |
| V | 2.6 | 0.7 | 1.9 | 6 | 61–70 | F | 10 | 133 | 13 | Pos |
| CX | 2.6 | 0.7 | 1.9 | 1.5 | 61–70 | F | 12 | 34 | 3 | Pos |
| AP | 3 | 1.1 | 1.9 | 3 | 51–60 | F | 8 | 88 | 11 | Pos |
| CS | 2.5 | 0.6 | 1.9 | 1.5 | 61–70 | F | 9 | 8 | - | Neg |
| AH | 2.7 | 0.9 | 1.8 | 3 | 41–50 | F | 10 | 114 | 11 | Pos |
| H | 2 | 0.4 | 1.6 | 6 | 51–60 | F | 109 | 365 | - | Baseline pos |
| AA | 2.5 | 0.9 | 1.6 | 3 | 51–60 | F | 25 | 59 | - | Baseline pos |
| AG | 2.5 | 0.9 | 1.6 | 3 | 51–60 | M | 11 | 23 | 2 | Pos |
| BK | 2.6 | 1 | 1.6 | 3 | 41–50 | M | 14 | 24 | 2 | Pos |
| S | 2.8 | 1.2 | 1.6 | 6 | 61–70 | F | 11 | 14 | - | Neg |
| AN | 2.9 | 1.3 | 1.6 | 3 | 41–50 | F | 16 | 5 | - | Neg |
| AU | 1.7 | 0.2 | 1.5 | 3 | 61–70 | M | 22 | 21 | - | Baseline pos |
| DK | 3 | 1.5 | 1.5 | 1.5 | 61–70 | F | 9 | 8 | - | Neg |
| AL | 2.7 | 1.3 | 1.4 | 3 | 51–60 | M | 11 | 52 | 5 | Pos |
| AI | 2.5 | 1.2 | 1.3 | 3 | 51–60 | F | 8 | 95 | 12 | Pos |
| AK | 2.9 | 1.6 | 1.3 | 3 | 61–70 | F | 15 | 7 | - | Neg |
| AE | 2.4 | 1.1 | 1.3 | 3 | 71–80 | M | 8 | 67 | 8 | Pos |
| T | 2.9 | 1.7 | 1.2 | 6 | 61–70 | M | 7 | 15 | - | Neg |
| AD | 2.3 | 1.1 | 1.2 | 3 | 51–60 | F | 50 | 41 | - | Baseline pos |
| DF | 2.6 | 1.5 | 1.1 | 1.5 | 51–60 | M | 6 | 4 | - | Neg |
| L | 1.4 | 0.3 | 1.1 | 6 | 61–70 | M | 23 | 209 | - | Baseline pos |
| AM | 3.3 | 2.2 | 1.1 | 3 | 51–60 | F | 6 | 6 | - | Neg |
| CE | 1.3 | 0.4 | 0.9 | 1.5 | 61–70 | M | 10 | 21 | 2 | Pos |
| DC | 2.9 | 2 | 0.9 | 1.5 | 51–60 | F | 7 | 5 | - | Neg |
| CA | 3.6 | 2.8 | 0.8 | 1.5 | 31–40 | F | 8 | 7 | - | Neg |
| DZ | 3.2 | 2.4 | 0.8 | 1.5 | 61–70 | F | 6 | 5 | - | Neg |
| CG | 2 | 1.3 | 0.7 | 1.5 | 61–70 | F | 6 | 8 | - | Neg |
| DQ | 2.9 | 2.2 | 0.7 | 1.5 | 61–70 | F | 4 | 3 | - | Neg |
| DY | 3 | 2.3 | 0.7 | 1.5 | 61–70 | F | 7 | 5 | - | Neg |
| DB | 2.9 | 2.2 | 0.7 | 1.5 | 41–50 | M | 9 | 6 | - | Neg |
| C | 1.1 | 0.5 | 0.6 | 6 | 21–30 | F | 74 | 239 | - | Baseline pos |
| CN | 3.1 | 2.5 | 0.6 | 1.5 | 71–80 | F | 14 | 11 | - | Neg |
| AT | 2.3 | 1.7 | 0.6 | 3 | 41–50 | M | 25 | 70 | - | Baseline pos |
| DG | 2.9 | 2.5 | 0.4 | 1.5 | 61–70 | F | 3 | 3 | - | Neg |
| U | 2.5 | 2.1 | 0.4 | 6 | 51–60 | F | 15 | 32 | 2 | Pos |
| DH | 3.3 | 3 | 0.3 | 1.5 | 61–70 | F | 6 | 4 | - | Neg |
| DW | 2.6 | 2.3 | 0.3 | 1.5 | 61–70 | M | 8 | 6 | - | Neg |
| A | 2.9 | 2.6 | 0.3 | 6 | 41–50 | F | 47 | 43 | - | Baseline pos |
| CB | 3 | 2.7 | 0.3 | 1.5 | 31–40 | F | 17 | 32 | 2 | Pos |
| CJ | 3 | 2.8 | 0.2 | 1.5 | 61–70 | F | 8 | 7 | - | Neg |
| DR | 2.9 | 2.7 | 0.2 | 1.5 | 61–70 | F | 8 | 6 | - | Neg |
| AO | 2.9 | 2.8 | 0.1 | 3 | 51–60 | M | 14 | 16 | - | Neg |
| DJ | 2.7 | 2.6 | 0.1 | 1.5 | 61–70 | F | 16 | 11 | - | Neg |
| Q | 2.8 | 2.7 | 0.1 | 6 | 61–70 | M | 13 | 32 | 2 | Pos |
| N | 2.7 | 2.7 | 0 | 6 | 51–60 | M | 8 | 10 | - | Neg |
| DN | 2.3 | 2.3 | 0 | 1.5 | 61–70 | M | 14 | 12 | - | Neg |
| DP | 2.8 | 2.8 | 0 | 1.5 | 51–60 | M | 7 | 6 | - | Neg |
| DM | 1.3 | 1.4 | -0.1 | 1.5 | 41–50 | F | 13 | 12 | - | Neg |
| AJ | 2.5 | 2.6 | -0.1 | 3 | 51–60 | F | 13 | 16 | - | Neg |
| DX | 2.9 | 3.1 | -0.2 | 1.5 | 61–70 | F | 10 | 6 | - | Neg |
| CT | 2.8 | 3 | -0.2 | 1.5 | 71–80 | M | 15 | 23 | 2 | Pos |
| AR | 2.3 | 2.6 | -0.3 | 3 | 51–60 | M | 13 | 22 | 2 | Pos |
| DA | 2.4 | 2.8 | -0.4 | 1.5 | 51–60 | F | 36 | 22 | - | Baseline pos |
| AX | 2.8 | 3.3 | -0.5 | 3 | 51–60 | M | 20 | 19 | - | Baseline pos |
| AB | 2.3 | 3.4 | -1.1 | 3 | 41–50 | M | 9 | 9 | - | Neg |
NOTE. Parameters associated with the gluten challenge included the amount of gluten ingested daily for 42 days, the age range (median, 59 y; range, 23–74 y), antisera directed against TG2-IgA (anti-TG2-IgA) expressed in intensity units for both baseline and 42 days, and anti–TG2-IgA that was positive (pos) or negative (neg) above threshold (20 intensity units) at 42 days. Several patients were above threshold for anti–TG2-IgA at baseline (baseline pos). Anti–TG2-IgA fold change was expressed in intensity units, which may or may not reflect linearity pending assay validation.
F, female; M, male.